# Monica Kraft

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 145 papers | 12,200 citations | 56 h-index | 109 g-index |
| 155 ext. papers | 13,939 ext. citations | 8.9 avg, IF | 5.79 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 145 | Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. *Journal of Allergy and Clinical Immunology*, **2010**, 126, S1-58 | 11.5 | 959 |
| 144 | Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. *Lancet, The*, **2004**, 364, 1505-12 | 40 | 532 |
| 143 | Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 116-24 | 10.2 | 520 |
| 142 | Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 583-93 | 10.2 | 517 |
| 141 | Significant variability in response to inhaled corticosteroids for persistent asthma. *Journal of Allergy and Clinical Immunology*, **2002**, 109, 410-8 | 11.5 | 500 |
| 140 | Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. *Journal of Allergy and Clinical Immunology*, **2011**, 127, 372-381.e1-3 | 11.5 | 486 |
| 139 | The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 162, 75-80 | 10.2 | 479 |
| 138 | Tiotropium bromide step-up therapy for adults with uncontrolled asthma. *New England Journal of Medicine*, **2010**, 363, 1715-26 | 59.2 | 385 |
| 137 | Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 175, 783-90 | 10.2 | 319 |
| 136 | Daily versus as-needed corticosteroids for mild persistent asthma. *New England Journal of Medicine*, **2005**, 352, 1519-28 | 59.2 | 299 |
| 135 | Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. *Chest*, **2002**, 121, 1782-8 | 5.3 | 288 |
| 134 | Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 998-1001 | 10.2 | 286 |
| 133 | A link between chronic asthma and chronic infection. *Journal of Allergy and Clinical Immunology*, **2001**, 107, 595-601 | 11.5 | 264 |
| 132 | beta-Adrenergic receptor polymorphisms and response to salmeterol. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 173, 519-26 | 10.2 | 262 |
| 131 | Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1295-302 | 11.5 | 224 |
| 130 | Systemic effect comparisons of six inhaled corticosteroid preparations. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1377-83 | 10.2 | 219 |
| 129 | IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. *Journal of Allergy and Clinical Immunology*, **2012**, 130, 829-42; quiz 843-4 | 11.5 | 188 |

| | | | |
|---|---|---|---|
| 128 | Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 311, 2083-91 | 27.4 | 179 |
| 127 | Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. *Lancet, The*, **2009**, 374, 1754-64 | 40 | 179 |
| 126 | Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. *American Journal of Respiratory and Critical Care Medicine*, **1999**, 159, 228-34 | 10.2 | 177 |
| 125 | Eosinophilic and Noneosinophilic Asthma. *American Journal of Respiratory and Critical Care Medicine* , **2018**, 197, 22-37 | 10.2 | 163 |
| 124 | Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 63-75 | 11.5 | 153 |
| 123 | Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. *Journal of Allergy and Clinical Immunology*, **2005**, 115, 720-7 | 11.5 | 150 |
| 122 | The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. *Journal of Allergy and Clinical Immunology*, **2007**, 119, 73-80 | 11.5 | 144 |
| 121 | Flow Cytometric Analysis of Myeloid Cells in Human Blood, Bronchoalveolar Lavage, and Lung Tissues. *American Journal of Respiratory Cell and Molecular Biology*, **2016**, 54, 13-24 | 5.7 | 131 |
| 120 | Diffusion-weighted hyperpolarized 129Xe MRI in healthy volunteers and subjects with chronic obstructive pulmonary disease. *Magnetic Resonance in Medicine*, **2011**, 65, 1154-65 | 4.4 | 129 |
| 119 | Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2012**, 308, 987-97 | 27.4 | 128 |
| 118 | Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 163, 1470-5 | 10.2 | 124 |
| 117 | Hyperpolarized Xe MR imaging of alveolar gas uptake in humans. *PLoS ONE*, **2010**, 5, e12192 | 3.7 | 120 |
| 116 | A trial of clarithromycin for the treatment of suboptimally controlled asthma. *Journal of Allergy and Clinical Immunology*, **2010**, 126, 747-53 | 11.5 | 115 |
| 115 | Chronic obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in healthy volunteers and patients. *Radiology*, **2012**, 262, 279-89 | 20.5 | 113 |
| 114 | Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. *Lancet Respiratory Medicine,the*, **2019**, 7, 402-416 | 35.1 | 108 |
| 113 | Asthma outcomes: pulmonary physiology. *Journal of Allergy and Clinical Immunology*, **2012**, 129, S65-87 | 11.5 | 102 |
| 112 | Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 676-87 | 10.2 | 98 |
| 111 | Physiologic correlates of distal lung inflammation in asthma. *Journal of Allergy and Clinical Immunology*, **2004**, 113, 1046-50 | 11.5 | 98 |

| | | | |
|---|---|---|---|
| 110 | Distal lung dysfunction at night in nocturnal asthma. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 163, 1551-6 | 10.2 | 94 |
| 109 | Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. *International Archives of Allergy and Immunology*, **2001**, 124, 183-6 | 3.7 | 92 |
| 108 | Predictors of response to tiotropium versus salmeterol in asthmatic adults. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1068-1074.e1 | 11.5 | 89 |
| 107 | S-nitrosoglutathione reductase: an important regulator in human asthma. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 226-31 | 10.2 | 87 |
| 106 | Substance P and its receptor neurokinin 1 expression in asthmatic airways. *Journal of Allergy and Clinical Immunology*, **2000**, 106, 713-22 | 11.5 | 82 |
| 105 | The role of bacterial infections in asthma. *Clinics in Chest Medicine*, **2000**, 21, 301-13 | 5.3 | 79 |
| 104 | Role of hyaluronan and hyaluronan-binding proteins in human asthma. *Journal of Allergy and Clinical Immunology*, **2011**, 128, 403-411.e3 | 11.5 | 78 |
| 103 | Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. *Journal of Allergy and Clinical Immunology*, **1999**, 103, 66-71 | 11.5 | 78 |
| 102 | The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. *Chest*, **1997**, 111, 1249-54 | 5.3 | 72 |
| 101 | Serum lidocaine concentrations in asthmatics undergoing research bronchoscopy. *Chest*, **2000**, 117, 1055-60 | 5.3 | 72 |
| 100 | Theophylline: potential antiinflammatory effects in nocturnal asthma. *Journal of Allergy and Clinical Immunology*, **1996**, 97, 1242-6 | 11.5 | 71 |
| 99 | Investigative bronchoprovocation and bronchoscopy in airway diseases. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 807-16 | 10.2 | 68 |
| 98 | Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-1 in airway fibroblasts in asthma. *European Respiratory Journal*, **2014**, 43, 464-73 | 13.6 | 66 |
| 97 | Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 175, 228-34 | 10.2 | 65 |
| 96 | Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. *New England Journal of Medicine*, **2019**, 380, 2009-2019 | 59.2 | 64 |
| 95 | Quantitative analysis of hyperpolarized 129Xe ventilation imaging in healthy volunteers and subjects with chronic obstructive pulmonary disease. *NMR in Biomedicine*, **2013**, 26, 424-35 | 4.4 | 64 |
| 94 | Elevated serum melatonin is associated with the nocturnal worsening of asthma. *Journal of Allergy and Clinical Immunology*, **2003**, 112, 513-7 | 11.5 | 63 |
| 93 | Immunomodulatory effects of melatonin in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 1055-61 | 10.2 | 63 |

| | | | |
|---|---|---|---|
| 92 | Bacterial biogeography of adult airways in atopic asthma. *Microbiome*, **2018**, 6, 104 | 16.6 | 57 |
| 91 | IL-4, IL-13, and dexamethasone augment fibroblast proliferation in asthma. *Journal of Allergy and Clinical Immunology*, **2001**, 107, 602-6 | 11.5 | 57 |
| 90 | Alveolar macrophages from overweight/obese subjects with asthma demonstrate a proinflammatory phenotype. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 404-11 | 10.2 | 56 |
| 89 | Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible?. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 163, 1219-25 | 10.2 | 54 |
| 88 | Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. *Chest*, **2006**, 130, 1726-32 | 5.3 | 53 |
| 87 | Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel report. *Journal of the American Academy of Dermatology*, **2011**, 64, 175-92 | 4.5 | 52 |
| 86 | Airway fibroblasts exhibit a synthetic phenotype in severe asthma. *Journal of Allergy and Clinical Immunology*, **2005**, 115, 534-40 | 11.5 | 51 |
| 85 | Bronchial thermoplasty for severe asthma. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 709-14 | 10.2 | 47 |
| 84 | Microfluidic platform versus conventional real-time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimens. *Diagnostic Microbiology and Infectious Disease*, **2010**, 67, 22-9 | 2.9 | 41 |
| 83 | Surfactant protein A is defective in abrogating inflammation in asthma. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2011**, 301, L598-606 | 5.8 | 41 |
| 82 | Airway fibroblasts in asthma manifest an invasive phenotype. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1625-32 | 10.2 | 40 |
| 81 | The importance and features of the distal airways in children and adults. *Journal of Allergy and Clinical Immunology*, **2009**, 124, S84-7 | 11.5 | 39 |
| 80 | Effects of atypical infections with Mycoplasma and Chlamydia on asthma. *Immunology and Allergy Clinics of North America*, **2010**, 30, 575-85, vii-viii | 3.3 | 36 |
| 79 | Race is associated with differences in airway inflammation in patients with asthma. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 257-265.e11 | 11.5 | 34 |
| 78 | Epidemiology of asthma. *Clinics in Chest Medicine*, **2006**, 27, 1-15, v | 5.3 | 34 |
| 77 | Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. *New England Journal of Medicine*, **2019**, 381, 1227-1239 | 59.2 | 32 |
| 76 | Impact of Age and Sex on Response to Asthma Therapy. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 551-8 | 10.2 | 30 |
| 75 | Vitamin D Supplementation and the Risk of Colds in Patients with Asthma. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 634-41 | 10.2 | 30 |

| | | | |
|---|---|---|---|
| 74 | Use of biomarkers to identify phenotypes and endotypes of severeasthma. *Annals of Allergy, Asthma and Immunology*, **2018**, 121, 414-420 | 3.2 | 30 |
| 73 | Evaluation of blood vessels and edema in the airways of asthma patients: regulation with clarithromycin treatment. *Chest*, **2001**, 120, 416-22 | 5.3 | 30 |
| 72 | Chronic treatment in vivo with □adrenoceptor agonists induces dysfunction of airway (□2) -adrenoceptors and exacerbates lung inflammation in mice. *British Journal of Pharmacology*, **2012**, 165, 2365-77 | 8.6 | 29 |
| 71 | Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. *Chest*, **2003**, 124, 42-50 | 5.3 | 29 |
| 70 | Club Cell Secretory Protein Deficiency Leads to Altered Lung Function. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 302-312 | 10.2 | 27 |
| 69 | Altered pituitary-adrenal interaction in nocturnal asthma. *Journal of Allergy and Clinical Immunology* , **2003**, 112, 52-7 | 11.5 | 26 |
| 68 | Induction of regulated upon activation, normal T cells expressed and secreted (RANTES) and transforming growth factor-beta 1 in airway epithelial cells by Mycoplasma pneumoniae. *American Journal of Respiratory Cell and Molecular Biology*, **2003**, 29, 344-51 | 5.7 | 25 |
| 67 | Obese asthmatic patients have decreased surfactant protein A□levels: Mechanisms and implications. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 918-926.e3 | 11.5 | 24 |
| 66 | Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 823-829 | 10.2 | 23 |
| 65 | SP-A preserves airway homeostasis during Mycoplasma pneumoniae infection in mice. *Journal of Immunology*, **2009**, 182, 7818-27 | 5.3 | 23 |
| 64 | Obesity□s effect on asthma extends to diagnostic criteria. *Journal of Allergy and Clinical Immunology* , **2018**, 141, 1096-1104 | 11.5 | 21 |
| 63 | Asthma end points and outcomes: what have we learned?. *Journal of Allergy and Clinical Immunology*, **2006**, 118, S1-15 | 11.5 | 21 |
| 62 | Chronic Infection and Severe Asthma. *Immunology and Allergy Clinics of North America*, **2016**, 36, 483-502 | 3.3 | 20 |
| 61 | SHP-1 as a critical regulator of Mycoplasma pneumoniae-induced inflammation in human asthmatic airway epithelial cells. *Journal of Immunology*, **2012**, 188, 3371-81 | 5.3 | 19 |
| 60 | Increased matrix metalloproteinase-9 with elastolysis in nocturnal asthma. *Annals of Allergy, Asthma and Immunology*, **2003**, 90, 72-8 | 3.2 | 19 |
| 59 | Serum cortisol in asthma: marker of nocturnal worsening of symptoms and lung function?. *Chronobiology International*, **1998**, 15, 85-92 | 3.6 | 19 |
| 58 | Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. *European Respiratory Journal*, **2021**, 58, | 13.6 | 19 |
| 57 | Mycoplasma in severe asthma. *Journal of Allergy and Clinical Immunology*, **2006**, 117, 1197-8 | 11.5 | 17 |

| | | | |
|---|---|---|---|
| 56 | Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 1016-1026 | 11.5 | 17 |
| 55 | Genetic variation in SP-A2 leads to differential binding to Mycoplasma pneumoniae membranes and regulation of host responses. *Journal of Immunology*, **2015**, 194, 6123-32 | 5.3 | 16 |
| 54 | Development and validation of an electronic medical record (EMR)-based computed phenotype of HIV-1 infection. *Journal of the American Medical Informatics Association: JAMIA*, **2018**, 25, 150-157 | 8.6 | 16 |
| 53 | Surfactant protein-A inhibits mycoplasma-induced dendritic cell maturation through regulation of HMGB-1 cytokine activity. *Journal of Immunology*, **2010**, 185, 3884-94 | 5.3 | 16 |
| 52 | Airway remodeling from bench to bedside: current perspectives. *Clinics in Chest Medicine*, **2006**, 27, 71-85, vi | 5.3 | 16 |
| 51 | Update in Asthma 2014. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 157-63 | 10.2 | 15 |
| 50 | P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 28-33 | 10.2 | 14 |
| 49 | Management of Severe Asthma before Referral to the Severe Asthma Specialist. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 877-886 | 5.4 | 14 |
| 48 | Assessment of murine lung mechanics outcome measures: alignment with those made in asthmatics. *Frontiers in Physiology*, **2012**, 3, 491 | 4.6 | 14 |
| 47 | Expression of epithelial markers in nocturnal asthma. *Journal of Allergy and Clinical Immunology*, **1998**, 102, 376-81 | 11.5 | 14 |
| 46 | Mast cell TNF receptors regulate responses to Mycoplasma pneumoniae in surfactant protein A (SP-A)-/- mice. *Journal of Allergy and Clinical Immunology*, **2012**, 130, 205-14.e2 | 11.5 | 13 |
| 45 | Quality control within the Asthma Clinical Research Network. *Contemporary Clinical Trials*, **2001**, 22, 207S-21S | | 13 |
| 44 | A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). *Clinical and Experimental Allergy*, **2020**, 50, 1342-1351 | 4.1 | 13 |
| 43 | Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab. *Advances in Therapy*, **2018**, 35, 1059-1068 | 4.1 | 13 |
| 42 | Asthma and the host-microbe interaction. *Journal of Allergy and Clinical Immunology*, **2013**, 131, 1449-50e3 | 11.5 | 12 |
| 41 | Identification and Quantitation of Coding Variants and Isoforms of Pulmonary Surfactant Protein A. *Journal of Proteome Research*, **2014**, 13, 3722-32 | 5.6 | 11 |
| 40 | Part III: Location of asthma inflammation and the distal airways: clinical implications. *Current Medical Research and Opinion*, **2007**, 23 Suppl 3, S21-7 | 2.5 | 11 |
| 39 | Corticosteroids and leukotrienes: chronobiology and chronotherapy. *Chronobiology International*, **1999**, 16, 683-93 | 3.6 | 11 |

| | | | |
|---|---|---|---|
| 38 | Patient characteristics, biomarkers, and exacerbation risk in severe, uncontrolled asthma. *European Respiratory Journal*, **2021**, | 13.6 | 11 |
| 37 | Microbiome in Mechanisms of Asthma. *Clinics in Chest Medicine*, **2019**, 40, 87-96 | 5.3 | 11 |
| 36 | Role of Matrix Metalloproteinases-1 and -2 in Interleukin-13-Suppressed Elastin in Airway Fibroblasts in Asthma. *American Journal of Respiratory Cell and Molecular Biology*, **2016**, 54, 41-50 | 5.7 | 10 |
| 35 | Pharmacotherapy of severe asthma. *Current Opinion in Pharmacology*, **2010**, 10, 266-71 | 5.1 | 10 |
| 34 | Surfactant Protein-A Protects against IL-13-Induced Inflammation in Asthma. *Journal of Immunology*, **2020**, 204, 2829-2839 | 5.3 | 10 |
| 33 | Toll-Interacting Protein, Tollip, Inhibits IL-13-Mediated Pulmonary Eosinophilic Inflammation in Mice. *Journal of Innate Immunity*, **2018**, 10, 106-118 | 6.9 | 8 |
| 32 | Metalloproteinases as modulators of allergic asthma: therapeutic perspectives. *Metalloproteinases in Medicine*, **2015**, 61 | 0.7 | 8 |
| 31 | Nocturnal Asthma. *BioDrugs*, **1996**, 6, 443-453 | | 8 |
| 30 | Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma. *Immunity, Inflammation and Disease*, **2018**, 6, 322-331 | 2.4 | 7 |
| 29 | Tollip Inhibits ST2 Signaling in Airway Epithelial Cells Exposed to Type 2 Cytokines and Rhinovirus. *Journal of Innate Immunity*, **2020**, 12, 103-115 | 6.9 | 7 |
| 28 | Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma. *Journal of Asthma*, **1998**, 35, 261-5 | 1.9 | 6 |
| 27 | Genetic Variation in Surfactant Protein-A2 Delays Resolution of Eosinophilia in Asthma. *Journal of Immunology*, **2019**, 203, 1122-1130 | 5.3 | 5 |
| 26 | Interleukin-4 and interleukin-13 augment the proliferative effect of dexamethasone on distal lung fibroblasts. *Chest*, **2003**, 123, 356S | 5.3 | 5 |
| 25 | Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, | 5.4 | 5 |
| 24 | Targeted HAS2 Expression Lessens Airway Responsiveness in Chronic Murine Allergic Airway Disease. *American Journal of Respiratory Cell and Molecular Biology*, **2017**, 57, 702-710 | 5.7 | 4 |
| 23 | Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2015**, 12, 680-9 | 2 | 4 |
| 22 | CC16 Binding to β Integrin Protects against Infection. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1410-1418 | 10.2 | 4 |
| 21 | Asthma: Clinical Diagnosis and Management **2016**, 731-750.e7 | | 3 |

| | | | |
|---|---|---|---|
| 20 | Vitamin D Supplementation and the Risk of Colds in Patients with Asthma. *Journal of Allergy and Clinical Immunology*, **2015**, 135, AB109 | 11.5 | 3 |
| 19 | The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: an overview of Network organization, procedures and interventions. *Journal of Allergy and Clinical Immunology*, **2021**, | 11.5 | 3 |
| 18 | A 20-Mer Peptide Derived from the Lectin Domain of Decreases Tumor Necrosis Factor Alpha Production during Mycoplasma pneumoniae Infection. *Infection and Immunity*, **2020**, 88, | 3.7 | 2 |
| 17 | Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma. *The Lancet Child and Adolescent Health*, **2021**, 5, 862-872 | 14.5 | 2 |
| 16 | Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 3474-3481 | 5.4 | 2 |
| 15 | Meeting the obligation to balance bioethics and clinical trial design in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 648-50 | 10.2 | 1 |
| 14 | Does Mycoplasma Infection Change the Asthma Phenotype?. *Journal of Asthma*, **2009**, 46, 10-22 | 1.9 | 1 |
| 13 | Epidemiology of Asthma **2008**, 3-12 | | 1 |
| 12 | Genetic Variation in Surfactant Protein-A2 Results in Altered Regulation of Eosinophil Activities and Enhanced Eosinophilia in Patients with Asthma. *Annals of the American Thoracic Society*, **2016**, 13 Suppl 1, S101 | 4.7 | 1 |
| 11 | Bacteria in Asthma Pathogenesis. *Immunology and Allergy Clinics of North America*, **2019**, 39, 377-389 | 3.3 | 1 |
| 10 | Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era. *Contemporary Clinical Trials*, **2019**, 77, 98-103 | 2.3 | 1 |
| 9 | Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov. *Clinical Trials*, **2018**, 15, 87-94 | 2.2 | 1 |
| 8 | Myeloid-associated differentiation marker is a novel SP-A-associated transmembrane protein whose expression on airway epithelial cells correlates with asthma severity. *Scientific Reports*, **2021**, 11, 23392 | 4.9 | 0 |
| 7 | Small airways dysfunction: is there any involvement in patients with atopy? - AuthorsTreply. *Lancet Respiratory Medicine,the*, **2019**, 7, e27 | 35.1 | |
| 6 | Reply. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 713-714 | 11.5 | |
| 5 | Beyond the Dutch Hypothesis. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 1057-1057 | 16.2 | |
| 4 | Asthma. *Seminars in Respiratory and Critical Care Medicine*, **2002**, 23, 315-6 | 3.9 | |
| 3 | Chronic Infection and Severe Asthma. *Lung Biology in Health and Disease*, **2001**, 303-322 | | |

2 Into the deep; the role of the distal lung in asthma. *Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology*, **2004**, 18, 385-385 0.1

1 Anti-allergic Drugs **2008**, 281-286